Table 2.
Univariate analysis of risks of OS
| Univariate | ||
|---|---|---|
| HR | P value | |
| Age | 1.012 (1.006–1.018) | <0.001 |
| Male | 1.044 (0.932–1.170) | 0.453 |
| ALB | 0.991 (0.981–1.002) | 0.106 |
| FBG | 0.998 (0.992–1.004) | 0.59 |
| logCA199 | 1.318 (1.236–1.406) | <0.001 |
| TB | 1.000 (1.000–1.001) | 0.164 |
| Biliary drainage | 1.057 (0.929–1.203) | 0.398 |
| Body/tail | 1.085 (0.971–1.212) | 0.149 |
| Diagnostic year | 0.103 | |
| 2013 | Ref. | |
| 2014 | 1.029 (0.762–1.389) | 0.852 |
| 2015 | 1.204 (0.910–1.594) | 0.194 |
| 2016 | 0.937 (0.715–1.228) | 0.637 |
| 2017 | 1.120 (0.858–1.460) | 0.405 |
| 2018 | 1.153 (0.880–1.512) | 0.301 |
| 2019 | 0.960 (0.707–1.304) | 0.795 |
| ASA Score | 0.798 | |
| 1 | Ref. | |
| 2 | 0.977 (0.867–1.102) | 0.709 |
| 3 | 0.926 (0.748–1.148) | 0.485 |
| 4 | 1.180 (0.707–1.968) | 0.527 |
| Stage | <0.001 | |
| Ia | Ref. | |
| Ib | 1.168 (1.508–1.946) | 0.002 |
| IIa | 1.618 (1.186–2.207) | 0.002 |
| IIb | 2.197 (1.717–2.811) | <0.001 |
| III | 3.213 (2.512–4.110) | <0.001 |
| IV | 6.307 (4.831–8.235) | <0.001 |
| Differentiation | <0.001 | |
| I | Ref. | |
| II | 2.645 (0.372–18.835) | 0.331 |
| III | 3.941 (0.554–28.008) | 0.171 |
| IV | 41.974 (2.616–673.418) | 0.008 |
| Unknown | 1.399 (0.127–15.446) | 0.784 |
| Chemotherapy | 0.511 (0.458–0.570) | <0.001 |
| Surgical intervention | 0.254 (0.207–0.309) | <0.001 |
| BMI | 0.964 (0.946–0.983) | <0.001 |
| X-Tile categorizing | <0.001 | |
| < 18.9 | Ref. | |
| 18.9–23.3 | 0.745 (0.626–0.886) | 0.001 |
| ≥ 23.3 | 0.665 (0.556–0.794) | <0.001 |
| WHO categorizing | <0.001 | |
| < 18.5 | Ref. | |
| 18.5–23 | 0.625 (0.514–0.759) | <0.001 |
| ≥ 23 | 0.563 (0.462–0.685) | <0.001 |
ALB Albumin, FBG Fasten blood glucose, TB Total bilirubin, HR Hazard ratio, Ref Reference